Mecanismos moleculares envolvidos na resposta anti-tumoral e resistência a atra / Molecular mechanisms envolved in the anti-tumoral response and resistance to atRA

AUTOR(ES)
DATA DE PUBLICAÇÃO

2005

RESUMO

Gliomas are among the most common primary tumors of the central nervous system. Despite the advances in surgical and radiotherapy procedures and chemotherapy protocols, efficient treatment is still not available. Retinoic acid is a anti-proliferative agent used for treatment of a number of pre-malignant lesions and tumors, as promyelocytic leukemia. However, its clinical use in treatment of solid tumors, including gliomas, is impaired by the rapid development of resistance to the anti-tumoral effects of atRA. In order to address this problem, we proposed: a) to clone and analyze the role of rat cyp26b1, a member of cytochrome P450 superfamily envolved in the metabolization of retinoic acid, which has previously been described by our group as being potentially involved in the response of glioma cells to retinoic acid treatment; b) to generate and characterize a variant of rat C6 glioma cell line resistant to anti proliferative effects of atRA. The previously unknown cDNA of rat cyp26b1 was successfully amplified, cloned and sequenced. The protein is conserved and clustered in dendrograms with other cyp26b1 proteins, even from distant organisms as zebrafish, in detriment of other cyp26 paralogs. Cyp26b1 is strongly induced by atRA in rat and human glioma cells, in a dose-dependent fashion. Although expressed in human normal brains and glioma samples, no significant differences were found among different tumor grades nor comparing to normal brain. Stable-transfection and overexpression of rat cyp26b1 in rat and human glioma cell lines, as well as P19 mouse teratocarcinoma cell line, did not significantly modified cell growth properties, either on solid or semi-solid substrates. Prolonged treatment of C6 rat glioma cell line with atRA leads to isolation of an atRA-resistant polyclonal cell population, from which a resistant clonal cell line was successfully isolated. This clonal variant, named C6R cell line, displayed diminished growth inhibition by atRA compared to the parental C6 cell line and the variant ST1 cell line. In addition, this variant also showed a trend, although not quite statistically significant, to generate larger tumors when xenografted s.c. into nude mice. Expression of genes previously described as being induced by atRA-treatment in ST1 cells is strongly impaired in the C6R resistant cell line. In addition, lower expression of RARβ, RARγ and CRABP-1 was also observed in C6R cells, whereas a much higher expression of RXRγ and CRABP-2 was found in the resistant cells when compared to the parental C6 cells. As general conclusions of this work, we found that cyp26b1 is more likely to be involved in primary atRA metabolism and detoxification and does not seem to be an effector of atRA-induced cell growth arrest nor to be related to the resistance of glioma cells to atRA treatment. On the other hand, isolation and characterization of an atRA-resistant cell line suggests that atRA resistance is more likely to be due to differential expression of retinoid receptors and retinoic acid binding proteins.

ASSUNTO(S)

Ácido retinóico citocromo p450 glioma anti-tumoral glioma retinoic acid anti-tumoral cytochrom p450

ACESSO AO ARTIGO

Documentos Relacionados